Tourmaline Bio Performance
| TRMLDelisted Stock | 47.98 0.00 0.00% |
Tourmaline Bio has a performance score of 16 on a scale of 0 to 100. The entity has a beta of 1.12, which indicates a somewhat significant risk relative to the market. Tourmaline Bio returns are very sensitive to returns on the market. As the market goes up or down, Tourmaline Bio is expected to follow. Tourmaline Bio right now has a risk of 0.0497%. Please validate Tourmaline Bio treynor ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to decide if Tourmaline Bio will be following its existing price patterns.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tourmaline Bio are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent primary indicators, Tourmaline Bio is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 141 M | |
| Total Cashflows From Investing Activities | -194.3 M |
Tourmaline |
Tourmaline Bio Relative Risk vs. Return Landscape
If you would invest 4,789 in Tourmaline Bio on October 8, 2025 and sell it today you would earn a total of 9.00 from holding Tourmaline Bio or generate 0.19% return on investment over 90 days. Tourmaline Bio is currently generating 0.0104% in daily expected returns and assumes 0.0497% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Tourmaline, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tourmaline Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tourmaline Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tourmaline Bio, and traders can use it to determine the average amount a Tourmaline Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2101
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TRML |
Based on monthly moving average Tourmaline Bio is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tourmaline Bio by adding it to a well-diversified portfolio.
Tourmaline Bio Fundamentals Growth
Tourmaline Stock prices reflect investors' perceptions of the future prospects and financial health of Tourmaline Bio, and Tourmaline Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tourmaline Stock performance.
| Return On Equity | -0.3 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 993.63 M | |||
| Shares Outstanding | 25.69 M | |||
| Price To Book | 4.75 X | |||
| EBITDA | (89.73 M) | |||
| Total Debt | 244 K | |||
| Book Value Per Share | 10.09 X | |||
| Cash Flow From Operations | (77.26 M) | |||
| Earnings Per Share | (3.44) X | |||
| Total Asset | 309 M | |||
| Retained Earnings | (135.26 M) | |||
About Tourmaline Bio Performance
By examining Tourmaline Bio's fundamental ratios, stakeholders can obtain critical insights into Tourmaline Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Tourmaline Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about Tourmaline Bio performance evaluation
Checking the ongoing alerts about Tourmaline Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tourmaline Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tourmaline Bio is not yet fully synchronised with the market data | |
| Tourmaline Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (73.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tourmaline Bio generates negative cash flow from operations | |
| Over 89.0% of the company shares are owned by institutional investors |
- Analyzing Tourmaline Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tourmaline Bio's stock is overvalued or undervalued compared to its peers.
- Examining Tourmaline Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tourmaline Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tourmaline Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tourmaline Bio's stock. These opinions can provide insight into Tourmaline Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Tourmaline Stock
If you are still planning to invest in Tourmaline Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tourmaline Bio's history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |